NASH (nonalcoholic steatohepatitis), diabetes, and macrovascular disease: multiple chronic conditions and a potential treatment at the metabolic root

References

• Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686–690.PUBMED: pubmed/24042449.
   PubMed Web of Science ®Google Scholar
• Rinella M, Charlton M. The globalization of nonalcoholic fatty liver disease: prevalence and impact on world health. Hepatology. 2016;64:19–22.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA. Banting lecture. From the triumvirate toe the ominous octet: a new paradigm for the treatment of type 2 diabetes. Diabetes. 2009;58:773–795.
   PubMed Web of Science ®Google Scholar
• Accilli D. Insulin action research and the future of diabetes treatment: the 2017 Banting metal for scientific achievement lecture. Diabetes. 2018;67:1701–1709.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Golabi P, de Avila L, et al. Global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71:793–801.
   PubMed Web of Science ®Google Scholar
• Lomonaco R, Bril F, Portillo-Sanchez P, et al. Metabolic impact of nonalcoholic steatohepatitis in obese patients with type 2 diabetes. Diabetes Care. 2016;39:632–638.
   PubMed Web of Science ®Google Scholar
• Bazick J, Danithan M, Neuschwandwe-Tetri BA, et al. Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD: guidelines for referral in NALFD. Diabetes Care. 2015;38:1347–1355.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Chalasani N, Krowdley KV, et al. Pioglitazone, vitamin E, or Placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675–1685.
   PubMed Web of Science ®Google Scholar
• Taylor KS, Heneghan CJ, Farmer AJ. All-cause and cardiovascular mortality in middle-aged people with type 2 diabetes compared to people without diabetes in a large UK primary care database. Diabetes Care. 2013;36:2366–2371.
   PubMed Web of Science ®Google Scholar
• Golabi P, Otgonsuren M, de Avila L, et al. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine (Baltimore). 2018;97:e 0124.
   Web of Science ®Google Scholar
• Srinivasan M, Kamath P, Bhat N. Basal hyperinsulinemia beyond a threshold predicts major adverse cardiac events at 1 year after coronary angiogram in type 2 diabetes mellitus: a retrospective cohort study. Diabetes Metab Syndr. 2017;9:38.
   Google Scholar
• Kumar A, Patel DR, Wolski KE. Baseline fasting plasma insulin levels predict risk for major adverse cardiovascular events among patients with diabetes and high risk vascular disease: insights from the ACCELERATE trial. Diab Vasc Dis Res. 2019;16:171–177.
   PubMed Web of Science ®Google Scholar
• Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607.
   PubMed Web of Science ®Google Scholar
• Bergman RN, Piccinini F, Kabir M, et al. Novel aspects of the role of the liver in carbohydrate metabolism. Metabolism. 2019;pii S0026-0495(19):30099–X.
   Google Scholar
• Colca JR, Tanis SP, McDonald WG, et al. Insulin sensitizers in 2013: new insights for the development of novel therapeutic agents to treat metabolic diseases. Expert Opin Invest Drugs. 2014;23:1–7.
   PubMed Web of Science ®Google Scholar
• Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab. 2014;20(4):573–591.
   PubMed Web of Science ®Google Scholar
• Chen Y, Ma H, Zhu D, et al. Discovery of novel insulin sensitizers: promising approaches and targets. PPAR Res. 2017;2017: 1–13. Article ID 360919.
   Google Scholar
• DeFronzo RA, Inzucchi S, Abdul-Ghani M, et al. Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res. 2019;16:133–143.
   Web of Science ®Google Scholar
• Musso G, Cassader M, Paschetta E, et al. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis a meta analysis. JAMA Intern Med. 2017;177:633–640.
   PubMed Web of Science ®Google Scholar
• Colca JR. The TZD insulin sensitizer clue provides a new route into diabetes drug discovery. Expert Opin Drug Discov. 2015;10:1259–1270.
   PubMed Web of Science ®Google Scholar
• Tanis SP, Colca JR, Parker TT, et al. PPARγ-sparing thiazolidinediones as insulin sensitizers. Design, synthesis and selection of compounds for clinical development. Bioorg Med Chem. 2018 Dec 1;26(22):5870–5884.
   PubMed Web of Science ®Google Scholar
• Chen Z, Vigueira PA, Chambers KT, et al. Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor -sparing thiazolidinedione. J Biol Chem. 2012;287:23537–23548.
   PubMed Web of Science ®Google Scholar
• Colca JR, McDonald WG, Cavey GS, et al. Identification of a Mitochondrial Target of Thiazolidinedione Insulin Sensitizers (mTOT)-relationship to newly identified mitochondrial pyruvate carrier proteins. PLoS ONE. 2013;8:e61551:1–10.
   Web of Science ®Google Scholar
• Colca JR, McDonald WG, Kletzien RF. Mitochondrial target of thiazolidinediones. Diabetes Obes Metab. 2014;16(11):1048–1054.
   PubMed Web of Science ®Google Scholar
• McCommis KS, Finck BN. Mitochondrial pyruvate transport: a historical perspective and future research directions. Biochem J. 2015;466(3):443–454.
   PubMedGoogle Scholar
• McCommis KS, Hodges WT, Brunt EM, et al. Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis. Hepatology. 2017;65:1543–1556.
   PubMed Web of Science ®Google Scholar
• Rauckhorst AJ, Gray LR, Sheldon RD, et al. The mitochondrial pyruvate carrier mediates high fat diet-induced increases in hepatic TCA cycle capacity. Mol Metab. 2017;6(11):1468–1479.
   PubMed Web of Science ®Google Scholar
• Sharma A, Oonthonpan L, Sheldon RD, et al. Impaired skeletal muscle mitochondrial pyruvate uptake rewires glucose metabolism to drive whole-body leanness. Elife. 2019 Jul 18;8:pii: e45873.
   Web of Science ®Google Scholar
• Colca JR, McDonald WG, Adams WJ. MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis. Expert Opin Invest Drugs. 2018;27:631–636.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Alkhouri N, Davidson BA, et al. Insulin sensitizer MSDC-0602K in nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b study. J Hepatol. 2019. in press. PUBMED: pubmed/31697972.
   Google Scholar
• Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011;53(6):1883–1894.
   PubMed Web of Science ®Google Scholar
• Unalp-Arida A, Ruhl CE. PNPLA3 I148M and liver fat and fibrosis scores predict liver disease mortality in the United States population. Hepatology. 2019 Nov 9. Epub ahead of print. DOI:10.1002/hep.31032
   PubMedGoogle Scholar
• BasuRay S. PNPLA3-I148M: a problem of plenty in non-alcoholic fatty liver disease. Adipocyte. 2019;8(1):201–208.
   PubMed Web of Science ®Google Scholar
• Grant RW, Moore AF, Florez JC. Genetic architecture of type 2 diabetes: recent progress and clinical implications. Diabetes Care. 2009;32(6):1107–1114.
   PubMed Web of Science ®Google Scholar
• Goodarzi MO, Palmer ND, Cui J, et al. Classification of type 2 diabetes genetic variants and a novel genetic risk score association with insulin clearance. J Clin Endocrinol Metab. 2019 Nov 12;pii:dgz198.
   Google Scholar
• Lloyd-Jones DM. Cardiovascular health and protection against CVD: more than the sum of the parts? Circulation. 2014 Nov 4;130(19):1671–1673.
   PubMed Web of Science ®Google Scholar
• Arnett DK, Blumenthal RS, Albert MA, et al. ACC/AHA guideline on the primary prevention of cardiovascular disease: executive Summary: a report of the American College of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2019;140(11):e563–e595.
   PubMed Web of Science ®Google Scholar
• Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330–344.
   PubMed Web of Science ®Google Scholar
• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20.
   PubMed Web of Science ®Google Scholar